Glenmark Pharmaceuticals bags approval for Teriflunomide tablets

The pharma major Glenmark has won final USFDA approval for Teriflunomide Tablets, 7 mg and 14 mg. The shares of the company rose 1.5 per cent in the early trade following the announcement.

Teriflunomide is a generic version of Aubagio 1 Tablets, 7 mg and 14 mg, of Sanofi-Aventis. The company has announced that with respect to 180-day generic drug exclusivity, the company is one of the first to submit a substantially complete ANDA for Teriflunomide Tablets of 7mg and 14mg. Glenmark, since after the approval is thus eligible for 180-day of shared generic drug exclusivity for the Teriflunomide Tablets.

Teriflunomide affects the immune system and reduces swelling and inflammation in the nervous system. Teriflunomide is used to reduce flare-ups in people with relapsing multiple sclerosis (MS).

Glenmark Pharmaceuticals is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology.

On Friday, the shares of the company opened at Rs. 671 per share against Thursday’s close of Rs. 664.45 on the BSE. At 10:40 hours, the share was trading at Rs. 660.50 per share, down by 0.59 per cent. The intraday high was Rs. 674.45 and intraday low was Rs. 657 per share on the BSE. Its 52-week high was Rs 711.55 and 52-week low was Rs. 483.60 per share on the BSE.

Meanwhile, BSE Sensex was at 35,531.06 level, up by 0.77 per cent and Nifty50 was at 10,691.80 level , up by 0.71 per cent.